• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体调节蛋白在正常人体肾脏中的定位。

Localization of the complement regulatory proteins in the normal human kidney.

作者信息

Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S

机构信息

Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.

出版信息

Kidney Int. 1994 Jul;46(1):89-96. doi: 10.1038/ki.1994.247.

DOI:10.1038/ki.1994.247
PMID:7523758
Abstract

The kidney is an organ where complement-mediated tissue injuries take place by various stimuli. To assess how the kidney is protected from the autologous complement attack, comparative localization of decay accelerating factor (DAF), membrane cofactor protein (MCP) and 20 kDa homologous restriction factor (HRF20) was studied in the normal human kidney. Specific monoclonal antibodies to DAF, MCP and HRF20 were used for the study. Studies by immunofluorescence and immunoelectron microscopy showed that the distribution of each protein in the kidney was complementary to each other in most parts. MCP and HRF20 were clearly seen in the glomerular capillaries, while DAF was only faintly observed. Juxtaglomerular apparatus was abundant in DAF and MCP but not in HRF20. HRF20 was most strongly expressed in the peritubular capillaries where MCP was not detectable. Basolateral membranes of the proximal tubules and collecting ducts expressed MCP strongly, while there was no expression of DAF in the proximal tubules. Interestingly, both DAF and MCP, which inhibit complement activation at C3/C4 level, were not expressed in the apical portion of the tubular cells including proximal tubule brush border. In contrast, HRF20 was expressed on the apical part of the tubules. Medullary interstitium strongly expressed MCP but not DAF. Based on these observations, we conclude that each segment of the kidney is protected from the complement attack by the different combination of complement regulatory proteins. We speculate that the tubular cells might be fragile when complements are activated inside the tubular lumen, because there is no expression of complement regulatory proteins which inhibit C3 convertase.

摘要

肾脏是一个因各种刺激而发生补体介导的组织损伤的器官。为了评估肾脏如何免受自身补体攻击,我们研究了衰变加速因子(DAF)、膜辅因子蛋白(MCP)和20 kDa同源限制因子(HRF20)在正常人类肾脏中的比较定位。使用了针对DAF、MCP和HRF20的特异性单克隆抗体进行研究。免疫荧光和免疫电子显微镜研究表明,每种蛋白质在肾脏中的分布在大多数部位相互补充。MCP和HRF20在肾小球毛细血管中清晰可见,而DAF仅微弱观察到。近球小体中DAF和MCP丰富,但HRF20不存在。HRF20在肾小管周围毛细血管中表达最强,而在那里检测不到MCP。近端小管和集合管的基底外侧膜强烈表达MCP,而近端小管中没有DAF的表达。有趣的是,在包括近端小管刷状缘在内的肾小管细胞顶端部分,抑制C3/C4水平补体激活的DAF和MCP均未表达。相反,HRF20在肾小管顶端部分表达。髓质间质强烈表达MCP但不表达DAF。基于这些观察结果,我们得出结论,肾脏的每个节段通过补体调节蛋白的不同组合免受补体攻击。我们推测当补体在肾小管腔内被激活时,肾小管细胞可能很脆弱,因为没有抑制C3转化酶的补体调节蛋白的表达。

相似文献

1
Localization of the complement regulatory proteins in the normal human kidney.补体调节蛋白在正常人体肾脏中的定位。
Kidney Int. 1994 Jul;46(1):89-96. doi: 10.1038/ki.1994.247.
2
Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.补体调节蛋白CD21、CD55和CD59在伯基特淋巴瘤细胞系中的表达:它们在对人血清介导的细胞溶解敏感性中的作用。
Eur J Immunol. 1992 Jul;22(7):1871-6. doi: 10.1002/eji.1830220729.
3
Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter-associated gastritis.幽门螺杆菌相关性胃炎期间人胃上皮中补体膜抑制剂的表达改变
Histopathology. 1998 Dec;33(6):554-60. doi: 10.1046/j.1365-2559.1998.00539.x.
4
Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer.补体调节蛋白、衰变加速因子、CD59/同源限制因子20和膜辅助因子蛋白在人大肠腺瘤和癌中的分布
Acta Med Okayama. 1994 Oct;48(5):271-7. doi: 10.18926/AMO/31112.
5
Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver.人类胎儿早期的补体调节蛋白:CD59、膜辅助蛋白(MCP)和衰变加速因子(DAF)在发育中的肝脏中表达存在差异。
Immunology. 1993 Oct;80(2):183-90.
6
Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract.正常及患病人类胃肠道中细胞膜补体调节糖蛋白的表达
Gut. 1998 Apr;42(4):522-9. doi: 10.1136/gut.42.4.522.
7
Identification of the complement regulatory proteins CD46, CD55, and CD59 in human fallopian tube, endometrium, and cervical mucosa and secretion.在人输卵管、子宫内膜及宫颈黏膜和分泌物中补体调节蛋白CD46、CD55和CD59的鉴定。
Am J Reprod Immunol. 1995 Jul;34(1):1-9. doi: 10.1111/j.1600-0897.1995.tb00913.x.
8
Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis.溃疡性结肠炎结肠上皮细胞上衰变加速因子和CD59/同源限制因子20的表达增强。
Lab Invest. 1995 May;72(5):587-91.
9
Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis.
Immunology. 1994 Mar;81(3):452-61.
10
Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.肺癌中补体调节分子的水平:小细胞癌中CD55的D17表位消失。
Jpn J Cancer Res. 1993 Jul;84(7):753-9. doi: 10.1111/j.1349-7006.1993.tb02040.x.

引用本文的文献

1
Complement Activation is More Pronounced in the Kidneys of Critically Ill Patients With COVID-19 Than in Those With Bacterial Sepsis.与细菌性脓毒症患者相比,新冠重症患者肾脏中的补体激活更为明显。
Kidney Int Rep. 2025 Apr 21;10(7):2284-2295. doi: 10.1016/j.ekir.2025.04.027. eCollection 2025 Jul.
2
Urine complement analysis implies complement activation is involved in membranous nephropathy.尿液补体分析表明补体激活参与膜性肾病。
Front Med (Lausanne). 2025 Feb 13;12:1515928. doi: 10.3389/fmed.2025.1515928. eCollection 2025.
3
Exploring Potential Complement Modulation Strategies for Ischemia-Reperfusion Injury in Kidney Transplantation.
探索肾移植中缺血再灌注损伤的潜在补体调节策略。
Antioxidants (Basel). 2025 Jan 8;14(1):66. doi: 10.3390/antiox14010066.
4
Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases.顶端肾小管补体激活与蛋白尿性肾脏疾病中的肾功能丧失
Clin Kidney J. 2024 Jul 10;17(8):sfae215. doi: 10.1093/ckj/sfae215. eCollection 2024 Aug.
5
Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy.狼疮性足细胞病患者急性肾损伤和肾脏复发的危险因素。
Clin Kidney J. 2024 May 10;17(6):sfae148. doi: 10.1093/ckj/sfae148. eCollection 2024 Jun.
6
Filtration and tubular handling of EWE-hC3Nb1, a complement inhibitor nanobody, in wild type mice and a mouse model of proteinuric kidney disease.野生型小鼠和蛋白尿性肾病小鼠模型中补体抑制剂纳米抗体EWE-hC3Nb1的滤过及肾小管处理情况
FEBS Open Bio. 2024 Feb;14(2):322-330. doi: 10.1002/2211-5463.13752. Epub 2024 Jan 4.
7
In Vivo Assessment of Laboratory-Grown Kidney Tissue Grafts.实验室培育的肾组织移植物的体内评估
Bioengineering (Basel). 2023 Oct 29;10(11):1261. doi: 10.3390/bioengineering10111261.
8
The role of complement in kidney disease.补体在肾脏疾病中的作用。
Nat Rev Nephrol. 2023 Dec;19(12):771-787. doi: 10.1038/s41581-023-00766-1. Epub 2023 Sep 21.
9
Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease.靶向补体 C5a 受体在糖尿病肾病中的治疗潜力。
Int J Mol Sci. 2023 May 15;24(10):8758. doi: 10.3390/ijms24108758.
10
Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.活性抗体介导的肾脏排斥反应中端补体表达微弱。
Front Immunol. 2022 Apr 13;13:845301. doi: 10.3389/fimmu.2022.845301. eCollection 2022.